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Abstract
Background: Tobacco smoking is a major burden on the Australian population in terms of health, social and
economic costs. Because of this, in 2008, all Australian Governments agreed to set targets to reduce prevalence of
smoking to 10 % by 2018 and subsequently introduced several very strong anti-smoking measures. On this backdrop,
we estimated in 2012-13 the impact of several scenarios related to reduction of smoking prevalence to 10 % across the
entire Australian population and for below specific ages, on improving life expectancy.
Methods: Using the risk percentiles method the Australian Diabetes, Obesity and Lifestyle (AUSDIAB) baseline survey
and the Australian Bureau of Statistics (ABS) age-sex specific death counts were analyzed.
Results: Amongst men the gains in life expectancy associated with 10 % smoking prevalence are generally greater
than those of women with average life expectancy for men increasing by 0.11 to 0.41 years, and for women by 0.12 to
0.29 years. These are at best 54 % and 49 % for men and women of the gains achieved by complete smoking cessation.
The gains plateau for interventions targeting those <70 and <80 years. Amongst smokers the potential gains are much
greater, with an increase in average life expectancy amongst men smokers of 0.43 to 2.08 years, and 0.73 to 2.05 years
amongst women smokers. These are at best 46 % and 38 % for men and women smokers of the gains achieved by
complete smoking cessation.
Conclusion: The estimated optimum gain in life expectancy is consistent with potentially moderate gains which occur
when both men and women below 60 years are targeted to reduce smoking prevalence to 10 %.
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What this paper adds?
This is the first study in Australia evaluating the impact
of the smoking reduction target set by various Australian
governments by 2018, on improving life expectancy. It
achieves this objective by estimating the magnitude of
gain in life expectancy if the smoking reduction target is
met and by how much this accounts for the maximum
gain in life expectancy if complete smoking cessation is
achieved. This study provides direction on how to better
target the Australian adult population by their basic
demographics such as age and gender rather than by
only targeting the entire adult population ignoring their
age and gender. In view of its importance to smoking
control and its likely impact on health in general, the
paper is important for assessing the role of tobacco con-
trol policies on improvements in general health and
wellbeing. It discusses whether the set target is achiev-
able by 2018 and points out to further research in terms
of the impact on survival with further reduction in
smoking than has been targeted.
What is already known?
It is already known that the smoking prevalence has
been targeted to reduce to 10 percent by 2018 in
Australia. It is also known that this will improve average
life expectancy of the Australians.
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Highlights
● Amongst men the potential gains in life expectancy
associated with 10 % smoking prevalence are greater
than those of women, likely due to the higher baseline
prevalence in men.
● The maximal gain in life expectancy for reducing
smoking prevalence to 10 % at the population level oc-
curred when men and women below 60 years were
targeted.
● These are at best 54 % and 49 % for men and
women respectively of the life expectancy gains achieved
by complete smoking cessation in the population
● These are at best 46 % and 38 % for men and
women smokers.
Background
Tobacco smoking is a major burden on the Australian
community in terms of health, social and economic
costs. Smoking contributes to the development of all
major chronic diseases, including heart disease and
stroke, cancer, and respiratory disease. It is the largest
cause of premature death in Australia, contributing to
an estimated 15,000 deaths each year [1, 2]. In addition
to the direct costs associated with provision of care for
smoking related illnesses, additional costs to the com-
munity include loss of productivity due to absenteeism
or reduction in the workforce resulting from premature
death. Collins and Lapsley [1] estimated the total cost of
smoking to the Australian community to be $31.5 billion
in 2004-5. This represented an increase of 23.5 % over
five years, in the total costs estimated for 1998-99.
In 2008, through the Council of Australian Govern-
ments (COAG) National Healthcare Agreement and the
National Partnership Agreement on Preventive Health
[3], all Australian Governments agreed to set targets to
reduce the prevalence of adult daily smoking to 10 % by
2018, and to halve the rate of smoking amongst Torres
Strait Islander and Aboriginal people. To achieve this
target, the Australian government has introduced,
among others, plain packaging, graphic health warnings
on cigarette packages, 25 % tobacco excise increase in
April 2010 and record investment in anti-smoking social
marketing campaigns – one of the strongest measures
taken anywhere else in the developed world to curb
cigarette smoking. The 2009 National Preventive Health
Strategy [4] set out the actions recommended by the Na-
tional Preventive Taskforce to achieve these goals. The
National Tobacco Strategy 2012-2018 [5] takes account
of these key strategies and sets out a policy framework.
The health impact of achieving these Government tar-
gets for smoking prevalence is unknown.
Smoking prevalence in Australia varies across age
groups. In general, smoking prevalence decreases with
increasing age. In 2011-2012, Australians in the 25-34
year age group exhibited the highest rates for current
smoking with 23.9 % being current smokers. This was
followed by the age group 35-44 with 20.4 % being
current smokers. During the same period, 8.9 % of those
aged 65-74 were current smokers compared with 21.7 %
in the 45-54 year age group and 15.1 % in the 55-64 year
age group. Amongst younger Australians, smoking
prevalence was 6.6 % for those aged 15-17 years and
19.5 % for those aged 18-24 years [6].
In the context of the National Tobacco Strategy target
to reduce smoking prevalence in Australia to 10 % by
2018, this study aimed to model the impact of smoking
reduction on improvements in average life expectancies
in the Australian population. Although the prevalence of
smoking declines with age, the impact of targeting spe-
cific age groups for reduction of smoking prevalence in
terms of maximal impact on life expectancy is unknown.
In view of this we modelled scenarios in which smoking
prevalence were reduced to 10 % across the entire popu-
lation and below certain ages and estimated the impact
on life expectancy. All analyses were performed separ-
ately for men and women. This paper has important
health implications for Australia and because of the
novelty of setting national targets on smoking reduction,
has implications globally particularly for other developed
countries where such national targets are yet to be set.
Methods
We briefly describe the risk percentiles methodology
which is adapted from an earlier coronary heart dis-
ease (CHD) prevention model [7]. Based on the infor-
mation from the baseline survey of the AUSDIAB
study (described below) which we used in this study,
an all-cause mortality risk equation, the European
Cardiovascular SCORE or EURO SCORE [8] was ap-
plied to each individual and these were then ordered
to generate percentiles of mortality risk. The EURO
SCORE risk equation considered a binary
categorization for smoking status, namely, ‘current
smoker’ and ‘non-smoker’ and hence did not distin-
guish between ex-smoker and never smoker.
The overall population was evenly spread between the
percentiles of mortality risk; however the absolute risk
was higher in higher percentiles and vice versa. The ob-
served counts of deaths based on the national death
numbers were then allocated to each percentile of mor-
tality risk in proportion to the modelled level of absolute
risk in each percentile, enabling mortality rates to be cal-
culated for each percentile of risk. Using these mortality
rates life tables were then constructed for people at dif-
ferent percentiles or levels of risk, producing percentile-
risk-specific survival curves describing the survival ex-
perience (life expectancy) associated with each risk level.
Averaging these life expectancies over the population
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results in the population average life expectancy (ALE).
We term this the “Base Scenario”, meaning the ALE in the
population with its existing risk profile. For any hypothet-
ical intervention to reduce smoking prevalence there will
be a resulting change in the overall population risk factor
profile due to a certain proportion of smokers becoming
non-smokers which was obtained through Monte Carlo
simulation. Such individuals would then have reduced
risk, and their life expectancy altered according to this re-
duced risk. Averaging over the population produces the
average life expectancy associated with the particular
smoking intervention. The average life expectancy for
each intervention was then compared with that of the
“Base Scenario” to determine the impact of the interven-
tion at a population level. Further details of this method
and the calculations of ALE are provided in Additional file
1. Briefly, the steps for risk percentiles method are:
 Estimate risk scores for mortality for every individual
in our study cohort using the EURO SCORE.
 Divide the Australian population into mortality risk
percentiles using these risk scores.
 Use the ratios of the risk scores to allocate deaths in
the Australian population to risk percentiles.
 Divide these death counts by the age group-sex
specific Australian population to give us the mortal-
ity rate for each risk percentile group within each
sex and age group.
 Use these mortality rates to construct sex-specific
life tables for each risk percentile within each sex
group.
 Calculate a baseline average life expectancy (ALE)
per person for each sex.
 Use bootstrapping to construct confidence intervals
for ALE
 Change a certain percentage of current smokers to
non-smokers.
 Re-allocate participants to risk percentiles.
 Calculate the scenario ALE.
 Derive the effect of reductions in smoking
prevalence on mortality by calculating the gain in
life expectancy.
 Use bootstrapping to construct confidence intervals
of scenario ALE.
The EURO SCORE calibrates well to the Australian
population based on the baseline survey of the AUS-
DIAB study [9]. Although this risk equation was de-
veloped for those aged ≥40 years, we applied this to a
sample aged ≥25 years, which is valid under the as-
sumption that the ordering of risk in the age group
25-39 follows that of the ordering of risk based on
EURO SCORE.
The principal scenario modelled the impact on ALE of
achieving the National targets for smoking prevalence,
that is, a reduction from existing levels to 10 % by 2018.
A range of hypothetical intervention scenarios were
chosen to demonstrate the impact of targeting reduc-
tions in smoking prevalence in specific age groups. Once
the gains in life expectancy for the interventions were
estimated at the population level through the risk per-
centiles approach, they were approximated for the
smokers (the method is described in Additional file 1).
Table 1 summarises the smoking intervention scenarios
investigated using this model.
The baseline survey of the AUSDIAB study was a
cross-sectional, national, population-based survey con-
ducted in 1999–2000 [10]. In this survey, 11,190 partici-
pants (5,483 men and 5,707 women) aged > = 25 years
had complete data for a number of cardiovascular risk
factors including systolic and diastolic blood pressure,
self-reported cigarette smoking status, and serum total
cholesterol.
We obtained national population and death counts
classified by age and sex for the years 2001 to 2006 from
the Australian Institute of Health and Welfare (AIHW).
The population counts were derived from the Australian
Bureau of Statistics (ABS) mid-year population estimates
[11]. Death data was derived from the AIHW National
Mortality Database comprising all deaths registered in
Australia.
Results
In AUSDIAB the overall prevalence of current smoking
was 18.73 % for men and 13.16 % for women. Table 2
shows estimates of the national prevalence of current
smoking and number of (current) smokers by age and sex
obtained from the AUSDIAB baseline examination [12].
Table 3 shows the number of people who have to quit
smoking under each intervention scenario based on the
AUSDIAB baseline examination [12]. The number of quit-
ters increases disproportionately with age and slows down
after <60 years for men and after <50 years for women.
Table 4 shows the estimated mortality risks for the
smokers and nonsmokers (separately for men and
women) for all interventions if the smoking prevalence
and other risk factors during the baseline examination
remained unchanged. It shows that the mortality risks
for smokers are higher than nonsmokers in all interven-
tions. Men have higher mortality risks than women.
Tables 5 and 6 present the ALE and the gain in ALE
relative to the Base Scenario for each of the modelled
scenarios for women and men respectively. In comparison
to the Base Scenario there is a gain in ALE regardless of
the age at which people stop smoking.
The maximum gain in ALE occurs when everyone in
the population ceases smoking (0 % prevalence). The
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magnitude of this gain is 0.86 and 0.73 years for men
and women, respectively. The gain in ALE increases as
more of the older population is targeted, for both a tar-
get prevalence of 0 % and 10 %, respectively. However,
the additional gain in ALE for an intervention to achieve
a smoking prevalence target of 10 % is minimal when
persons at least age 60 are included in the intervention.
The maximal gain in ALE for men when prevalence in
each age intervention group is reduced to 10 % is ap-
proximately 54 % of the corresponding gain when
smoking is eliminated from the entire population, and
for women it is approximately 49 %.
Figure 1 depicts the gain in ALE results for women
summarised in Table 5. It presents the overall gain in
ALE by intervention scenario. For scenarios in which
smoking prevalence is reduced to 0 %, the smallest gain
in ALE occurs when only women less than 30 years are
targeted. The gain in ALE initially increases as older age
groups are included in the interventions; however the ef-
fect flattens when all individuals aged <70 years are in-
cluded. In comparison, for scenarios in which smoking
Table 1 Smoking Prevalence Scenarios Modelled With Mortality Projections (study period 2012-13)
Scenario Targeted Population Change in smoking behaviour
Base scenario Whole population No change
0 % prevalence <30 years 25-29 year age groups All smokers in targeted age group quit
10 % prevalence <30 years 25-29 year age groups Prevalence reduced to 10 % for both men and women aged <30 years
0 % prevalence <40 years 25-39 year age groups All smokers in targeted age group quit
10 % prevalence <40 years 25-39 year age groups Prevalence reduced to 10 % for both men and women aged <40 years
0 % prevalence <50 years 25-49 year age groups All smokers in targeted age group quit
10 % prevalence <50 years 25-49 year age groups Prevalence reduced to 10 % for both men and women aged <50 years
0 % prevalence <60 years 25-59 year age groups All smokers in targeted age group quit
10 % prevalence <60 years 25-59 year age groups Prevalence reduced to 10 % for both men and women aged <60 years
0 % prevalence <70 years 25-69 year age groups All smokers in targeted age group quit
10 % prevalence <70 years 25-69 year age groups Prevalence reduced to 10 % for both men and women aged <70 years
0 % prevalence <80 years 25-79 year age groups All smokers in targeted age group quit
10 % prevalence <80 years 25-79 year age groups Prevalence reduced to 10 % for both men and women aged <80 years
10 % prevalence in entire population Whole population Prevalence randomly reduced to 10 % for both men and women
0 % prevalence in entire population Whole population All smokers quit
Table 2 National Prevalence of Smoking in Australia as




Prevalence Smokers Prevalence Smokers
(Men) (Men) (Women) (Women)
25-29 25.60 175987 16.47 93153
30-34 22.30 166508 19.74 170786
35-39 26.07 172920 19.21 117507
40-44 21.24 165277 14.58 122826
45-49 19.58 116580 14.33 90297
50-54 19.21 123686 13.59 79154
55-59 15.97 72234 9.25 40025
60-64 11.06 39408 9.85 35656
65-69 12.02 44849 6.09 25581
70-74 5.77 17481 5.89 23537
75-79 4.70 8737 3.03 8472
80-84 5.07 5310 3.68 5172
85+ 1.19 374 0.14 55
Total 18.73 1109351 13.16 812221
Table 3 Estimated number of quitters to achieve each target
scenario (study period 2012-13)
Scenario Men Women
Base scenario ___ ___
0 % prevalence <30 years 175987 93153
10 % prevalence <30 years 107242 36594
0 % prevalence <40 years 515415 381446
10 % prevalence <40 years 305690 177212
0 % prevalence <50 years 797272 594569
10 % prevalence <50 years 450180 243064
0 % prevalence <60 years 993192 713748
10 % prevalence <60 years 536484 260724
0 % prevalence <70 years 1077448 774985
10 % prevalence <70 years 547770 243777
0 % prevalence <80 years 1103666 806994
10 % prevalence <80 years 525108 207900
10 % prevalence in entire population 517065 195032
0 % prevalence in entire population 1109351 812221
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prevalence is reduced to 10 %, the gain in ALE essen-
tially plateaus for interventions targeting additional indi-
viduals aged at least 60 years. Specifically, when smoking
prevalence is reduced to 10 % amongst women aged
<60 years, the gain in ALE is 0.29 years which is about
half of the maximum gain achievable through complete
cessation for that specific intervention. If women be-
tween 60 and 80 years are included in the targeted
population, there are no further gains in ALE. If smok-
ing is eliminated amongst all women the gain in ALE
is 0.73 years. In comparison, a reduction in smoking
prevalence to 10 % amongst all women realizes an
ALE gain of 0.27 years, i.e., reducing smoking preva-
lence to 10 % achieves only 37 % of the maximum
possible gain in ALE.
Figure 2 presents the corresponding gains in ALE for
men, as summarised in Table 6. This shows a similar
initial increase in ALE gain followed by a flattening of
the effect. When smoking prevalence is reduced to 10 %,
the plateauing effect again occurs at the point of inter-
vening on persons aged <60. This again indicates that
targeting smoking reduction in persons aged at least
60 years offers no additional gain in terms of population
ALE. The gain in ALE for reducing smoking prevalence
to 10 % for men aged <60 years is about 54 % of that ob-
tained by complete cessation for that target intervention.
When the entire population of men is targeted, the gain
in ALE is 0.86 years if smoking is eliminated, compared
to a gain in ALE of 0.39 years if prevalence is reduced to
10 %. Therefore, reducing prevalence to 10 % across the
population achieves only 45 % of the maximum possible
gain in ALE.
Table 7 summarizes the gains in ALE for female and
male current smokers if they were to cease smoking or if
Table 4 Mortality risks per 100,000 people by smoking status and sex for the interventions before any smoking reduction is
achieved using the AUSDIAB Baseline Examination (study period 2012-13)
Age
group
Current Smokers Non-smokers Current Smokers Non-smokers
(Men) (Men) (Women) (Women)
<30 85 40 4 2
<40 414 211 37 21
<50 1288 754 181 116
<60 2748 1749 608 419
<70 4520 3298 1200 1126
<80 5619 5417 2445 1981
All ages 6348 6009 3227 2242
Table 5 Gain in Average Life Expectancy (ALE) in the Whole Population Under Various Smoking Reduction Scenarios, for Women
(study period 2012-13)
Scenarios ALE (years) Gain in ALE relative to Base scenario (years)
Women 95 % CI Women 95 % CI
Base scenario 33.16 32.82,33.50 - -
0 % prevalence <30 years 33.31 32.95, 33.69 0.15 0.13,0.17
10 % prevalence <30 years* 33.28 32.92, 33.65 0.12 0.10,0.15
0 % prevalence <40 years 33.50 33.12, 33.85 0.34 0.30,0.36
10 % prevalence <40 years 33.38 33.00, 33.71 0.21 0.18,0.22
0 % prevalence <50 years 33.65 33.23,34.28 0.48 0.45,0.5
10 % prevalence <50 years 33.45 33.07, 33.78 0.26 0.24,0.28
0 % prevalence <60 years 33.75 33.34,34.18 0.59 0.51,0.68
10 % prevalence <60 years 33.45 33.09, 33.81 0.29 0.27,0.31
0 % prevalence <70 years 33.83 33.44,34.22 0.66 0.62,0.72
10 % prevalence <70 years 33.45 33.09, 33.81 0.29 0.27,0.31
0 % prevalence <80 years 33.88 33.54,34.22 0.71 0.7,0.72
10 % prevalence <80 years 33.44 33.07, 33.78 0.27 0.25,0.29
10 % prevalence in entire population 33.43 33.41, 33.47 0.27 −0.03 ,0.59
0 % prevalence in entire population 33.90 33.54,34.24 0.73 0.72,0.74
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prevalence were reduced to 10 %. Maximal gains if age
was targeted to reduce smoking prevalence to 10 % are
2.04 years for men and 2.00 years for women, both for age
group <80 years. However if smoking were to be elimi-
nated completely the gains in ALE in smokers would be
approximately 4.46 years for men and 5.27 years for
women for this intervention. Thus, if smoking prevalence
was reduced to 10 % by targeting the age groups, the max-
imal gains in ALE for men and women are about 46 %
and 38 % respectively of the maximum gains achievable
through complete smoking cessation.
Figures 3 and 4 present the gain in ALE results for
women and men smokers, as summarised in Table 7.
For scenarios in which smoking prevalence is reduced to
10 %, the smallest gain in ALE occurs when only women
less than 30 years are targeted (Fig. 3). As older age
groups are included in the intervention scenarios the
gain in ALE increases. However the gain in ALE begins
to plateau as women greater than 70 years are included
in the targeted population. A similar situation occurs for
men who smoke (Fig. 4), with ALE continuing to in-
crease as older age groups are included but slowing
down when men aged at least 70 years are included in
the targeted population.
Discussion
In this study we evaluated the impact of several smoking
prevalence reduction and cessation scenarios on average
life expectancy in Australia, with interventions targeting
increasingly older age groups. It was appropriate to relate
the gains by a reduced smoking prevalence to 10 %, to the
estimated gains in the case of total smoking cessation
Table 6 Gain in Average Life Expectancy (ALE) in the Whole Population Under Various Smoking Reduction Scenarios, for Men (study
period 2012-13)
Scenarios ALE (years) Gain in ALE relative to Base scenario (years)
Men 95 % CI Men 95 % CI
Base scenario 29.08 28.77,29.39 - -
0 % prevalence <30 years 29.23 28.86, 29.53 0.16 -.17,.44
10 % prevalence <30 years* 29.19 28.89, 29.50 0.11 0.10,0.12
0 % prevalence <40 years 29.48 29.15,29.79 0.40 0.36,0.43
10 % prevalence <40 years 29.34 29.02, 29.65 0.26 0.25,0.27
0 % prevalence <50 years 29.67 29.34,30.01 0.6 0.57,0.62
10 % prevalence <50 years 29.43 29.10, 29.75 0.358 0.330.36
0 % prevalence <60 years 29.82 29.18,30.46 0.74 0.62,0.82
10 % prevalence <60 years 29.48 29.16, 29.81 0.4 0.39,0.42
0 % prevalence <70 years 29.90 29.55,30.25 0.82 0.78,0.86
10 % prevalence <70 years 29.49 29.11, 29.87 0.41 0.1,0.82
0 % prevalence <80 years 29.92 29.47,30.18 0.85 0.8 ,0.89
10 % prevalence <80 years 29.47 29.09, 29.85 0.39 0.12,0.66
10 % prevalence in entire population 29.46 29.14, 29.81 0.39 0.36,0.43










































Age based intervention scenario*
10% prevalence
0% prevalence
Fig. 1 Overall gain in average life expectancy (ALE) for all women by intervention scenario. *For example, <40 indicates intervention to reduced
smoking for all individuals aged <40 years
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because the inclusion of complete cessation as a scenario
allowed us to quantify the maximal gain in average life ex-
pectancy which can be used as a benchmark with which
to compare gains from more realistic prevalence reduction
targets.
We found that reducing the prevalence of smoking in
the Australian population to 10 % could increase average
life expectancy of all men by approximately 0.1 to
0.4 years, and all women by approximately 0.1 to
0.3 years. These are at best 54 % and 49 % for men and
women respectively of the maximal life expectancy gains
that could be achieved by complete smoking cessation.
Amongst smokers the potential gains are greater, with an
increase in average life expectancy amongst men smokers
of approximately 0.4 to 2 years, and approximately 0.74 to
2 years amongst women smokers. However the gains in
life expectancy for men and women smokers associated
with 10 % smoking prevalence were at best 46 % and 38 %
respectively of the maximal gains achievable through
complete elimination of smoking. The maximal gains in
life expectancy for men and women associated with 10 %
smoking prevalence at the population level occurred when
both aged less than 60 years were targeted. This indicates
that including older people in the targeted population di-
lutes the effect of smoking reduction interventions, and
therefore concentrating smoking cessation programs on
populations aged less than 60 years represents a more op-
timal strategy.
As has been noted previously it is difficult to interpret












































Age based intervention scenario*
0% prevalence
10% prevalence
Fig. 2 Overall gain in average life expectancy (ALE) for all men by intervention scenario. *For example, <40 indicates intervention to reduced
smoking for all individuals aged <40 years
Table 7 Gain in Average Life Expectancy (ALE) Amongst Smokers in the Population Under Various Smoking Reduction Scenarios
(study period 2012-13)
Scenario Gain in ALE relative to base scenario (95 % CI)
Men Women
Base scenario - -
0 % prevalence <30 years 0.63(-0.66,1.72) 0.85 (0.79,0.91)
10 % prevalence <30 years 0.43 (0.39,0.47) 0.73 (0.61, 0.91)
0 % prevalence <40 years 1.63(1.46,1.75) 1.82 (1.61,1.93)
10 % prevalence <40 years 1.06 (1.02, 1.10) 1.12 (0.96, 1.18)
0 % prevalence <50 years 2.61 (2.48, 2.70) 2.84 (2.66, 2.96)
10 % prevalence <50 years 1.52 (1.44, 1.57) 1.54 (1.42, 1.66)
0 % prevalence <60 years 3.40 (2.85, 3.77) 3.74 (3.24, 4.32)
10 % prevalence <60 years 1.84 (1.79, 1.93) 1.84 (1.71, 1.97)
0 % prevalence <70 years 4.03 (3.83, 4.23) 4.52 (4.25, 4.94)
10 % prevalence <70 years 2.02 (0.49, 4.03) 1.99 (1.85, 2.12)
0 % prevalence <80 years 4.46 (4.19, 4.67) 5.27 (5.20, 5.35)
10 % prevalence <80 years 2.04 (0.63, 3.46) 2.00 (1.86, 2.15)
10 % prevalence in entire population 2.08 (1.92,2.30) 2.05 (-0.23, 4.48)
0 % prevalence in entire population 4.59 (3.84,5.34) 5.55 (5.47,5.62)
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any gains are usually averaged across an entire target
population and may range from just weeks to months
[13]. The target population will include individuals who
gain little additional life expectancy as well as individuals
who gain years of extra life. After reviewing 83 published
reports of gains in life expectancy from a range of med-
ical interventions, including both preventive measures
and disease treatments, Wright and Weinstein [13] con-
cluded that “a gain in life expectancy of a month from a
preventive intervention targeted at populations at aver-
age risk and a gain of a year from a preventive interven-
tion targeted at populations at elevated risk can both be
considered large”. Since our estimated maximal gains in
life expectancy to achieve a smoking prevalence of 10 %
is at best 0.4 years for men and 0.3 years for women, for
a population at an elevated risk of mortality such as
Australia, the results we have obtained are consistent
with potentially moderate or medium gains in life
expectancy if smoking prevalence could be reduced to
10 %, in line with the Government set targets. The
moderate gains in life expectancy at the population level
are plausible given the already relatively “low” smoking
prevalence in the population as the non-smokers dilute
them. However, the gains are large when considering
smokers only. In other settings or countries with higher
baseline prevalence the gains would be larger at both the
population level and for smokers.
Previous studies often defined smoking reduction as at
least 50 % reduced from baseline at a population level
without targeting of specific age or sex groups [14, 15].
In contrast, our study targets specific age groupings for
each sex for reductions in smoking prevalence. Also, our
targets are defined according to policies adopted by
successive Australian governments to reduce smoking
prevalence to 10 % by 2018. This is the first study in
Australia which quantified improvements in survival due
to reductions in smoking prevalence amongst different
age and sex groups. It demonstrated a clear and positive
gradient in life expectancy with increasing reduction in
smoking prevalence in the Australian population.
We restricted our analysis to all-cause mortality as it
is an objective endpoint and is available for all individ-
uals in the AUSDIAB study. However, it is unclear



















Fig. 3 Overall gain in average life expectancy (ALE) for women smokers by intervention scenario. *For example, <40 indicates intervention to



















Figs. 4 Overall gain in average life expectancy (ALE) for men smokers by intervention scenario. *For example, <40 indicates intervention to
reduced smoking for men smokers aged <40 years
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studied on mortality translates to other health outcomes
such as major smoking related diseases and their associ-
ated disability burden. Further work is needed in this
area.
Whilst the analysis was performed in a cross-sectional
setting, the changes in the smoking behavior have pri-
marily long-term effects. The life table method enabled
us to estimate the long-term effect of smoking reduction
on life expectancy, on the assumption that the mortality
rate for each risk percentile which was estimated on the
basis of all baseline risk factors (for the baseline sce-
nario) and the simulated distribution of smoking having
a prevalence of 10 % and the actual baseline distribution
of other risk factors (for each intervention scenario),
would continue for the rest of the life of each member
of a risk percentile. We did not directly model the lag or
delay in the health benefits of smoking cessation. How-
ever, if there is any lag or delay in health benefits of quit-
ting, we do not anticipate that to be very significant at the
population level.
Although it is possible to estimate the number of
deaths prevented or reductions in mortality rate due to
reductions in smoking prevalence using the simpler
population attributable risk method, our research ques-
tion was to estimate improvements in life expectancy for
which the population attributable risk method alone is
not sufficient as an additional method, for example, the
life table method will also be required to estimate life ex-
pectancy using the mortality rate estimated by the popu-
lation attributable risk method. Since the risk percentiles
method already incorporates the life table, we can esti-
mate life expectancy as a direct output.
We gradually targeted ages <30 years, <40 years and so on
below higher ages to determine the age after which there is
no further gain in life expectancy or there is a slowing down
in the gain. Performing the analyses for ages 30+, 40+ and
so on would not have allowed us to achieve this objective
(and so were not performed in this study). Also, targeting
the population by below a certain age would be helpful to
target fewer people compared to targeting the entire
AUSDIAB sample based on the full age range of 25-80 + .
We targeted the current smokers to quit smoking in
order to reduce smoking prevalence to 10 %. The issue
of ex-smokers having higher risk of mortality than never
smokers could not be modelled because the EURO
SCORE [8] did not make any distinction between ex-
smokers and never smokers while estimating risk scores
as the risk equation which was used to estimate these
had only two categories for smoking-current smokers
and nonsmokers (nonsmokers included both ex-smokers
and never smokers). In effect, the mortality rates among
never and former smokers were averaged. The inability
to distinguish between never and former smokers while
estimating absolute risk of individuals is a limitation of
this study. Despite this limitation of the EURO SCORE, it
was found to recalibrate well to the AUSDIAB sample [9].
Since the smoking prevalence estimated using the
1999-2000 (baseline) AUSDIAB survey is approximately
16 %, the projected target of 10 % by 2018 seems super-
ficially achievable. However, using dynamic forecasting
modelling Gartner et al. [16] found that as the initiation
rate has been declining in Australia, to achieve 10 %
prevalence by 2020, the current cessation rate should be
doubled. However, latest estimates in Australia indicate
that the smoking rate among adults aged 14 years and
over was 12.8 % and for 18 years and over was 13.3 % in
2013 [17]. There was a statistically significant decline be-
tween 2010 and 2013-the period during which the gov-
ernment target to achieve 10 % prevalence by 2018 was
well in force. With 5 years remaining to reach 2018
since 2013, the target of achieving 10 % prevalence by
2018 seems to be achievable.
Since we have shown that 10 % smoking prevalence
gives at best half of maximum possible gains under the
scenario of complete cessation, further modelling will
help to answer questions such as whether reduction of
smoking prevalence to 5 % will remediate most of, or lit-
tle of, the differential between reduction to 10 % preva-
lence and complete cessation. To achieve a target of 5 %
we modelled for men and women gains in life expect-
ancy for a few selected scenarios (results not shown),
like the random reduction to a smoking prevalence of
5 % for the whole population and random reduction to
5 % prevalence for those below 60 years, and found that
there was almost a proportionate decrease in gains in life
expectancy compared to the corresponding scenario
with a target of 10 % prevalence. The potential gains for
men and women were at best 0.63 and 0.5 years which
are 73 % and 68 % respectively of that obtained by
complete smoking cessation. Thus, setting a target of
5 % prevalence would remediate most of the differential
between reduction to 10 % prevalence and complete ces-
sation. The analysis and issues presented in this paper are
highly complex and as is the case in all scientific endeav-
ours, there is always a possibility that methodological
problems may affect the results and interpretation of the
findings. One major concern is obviously the cross-
sectional approach.
Conclusion
This study suggests that smoking cessation programs
aimed at reducing smoking prevalence in the Australian
population to 10 % could have a moderate or medium
impact on increasing average life expectancy, but a large
impact on smokers average life expectancy The target of
10 % smoking prevalence offers at best 54 % of the po-
tential life expectancy gains that could be achieved by
complete elimination of smoking.
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